• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by David Christopher Mehlin

    6/2/23 4:05:37 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials
    Get the next $NVOS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    David Christopher Mehlin

    (Last) (First) (Middle)
    C/O NOVO INTEGRATED SCIENCES, INC.
    11120 NE 2ND STREET, SUITE 100

    (Street)
    BELLEVUE WA 98004

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Novo Integrated Sciences, Inc. [ NOVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    COO & President
    3. Date of Earliest Transaction (Month/Day/Year)
    05/31/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 81,950 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy)(1) $0.132(1) 05/31/2023 A 2,000,000(1) 05/31/2023(1) 05/31/2029 Common Stock 2,000,000 $0 2,000,000 D
    Explanation of Responses:
    1. Represents the grant, by the issuer's Board of Directors, of an option to purchase 2,000,000 shares of the issuer's common stock at an exercise price of $0.132 per share. The option was fully vested and exercisable on the date of grant and expires on May 31, 2029.
    /s/ Christopher David 06/02/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

      Novo Integrated Sciences, Inc. (OTC:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2024. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and

      12/18/24 4:05:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundation

      7/19/24 5:00:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetizatio

      7/18/24 4:05:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Novo Integrated Sciences Appoints New President

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim

      2/16/24 2:00:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio

      7/7/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Financials

    Live finance-specific insights

    See more
    • Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC

      Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic

      4/7/22 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient

      Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc

      11/30/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences and Novo Healthnet Limited Complete Acquisition of Acenzia

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st

      6/29/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer David Christopher Mehlin

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      9/12/24 6:05:09 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by David Christopher Mehlin

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      6/2/23 4:05:37 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Novo Integrated Sciences Inc.

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      8/10/22 1:01:17 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    SEC Filings

    See more
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/6/25 4:30:35 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/2/25 4:13:03 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      4/4/25 4:30:17 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

      SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/6/24 12:00:24 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

      SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/10/23 3:45:24 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Novo Integrated Sciences Inc.

      SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/8/22 4:28:22 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials